Table 3.
Change in subretinal fluid height, central macular thickness, and best-corrected visual acuity at baseline, 3-weeks post-treatment, and 6 weeks post-treatment in the selective retina therapy (SRT) group and control group.
| SRF Height (μm) | CMT (μm) | CCT (μm) | BCVA (LogMAR) | |||||
|---|---|---|---|---|---|---|---|---|
| Control Group | SRT Group | Control Group | SRT Group | Control Group | SRT Group | Control Group | SRT Group | |
| Baseline | 186.5 ± 84.1 | 173.4 ± 88.6 | 316.1 ± 94.0 | 335.0 ± 110.5 | 369.8 ± 76.2 | 351.4 ± 62.9 | 0.20 ± 0.14 | 0.25 ± 0.22 |
| 3 weeks (p-value) |
153.0 ± 95.2 (0.036 *) |
78.5 ± 89.8 (<0.001 *) |
293.2 ± 79.5 (0.109) |
261.0 ± 81.5 (<0.001 *) |
365.1 ± 70.4 (0.298) |
354.3 ± 59.9 (0.361) |
0.20 ± 0.14 (0.266) |
0.25 ± 0.24 (1.000) |
| 6 weeks (p-value) |
158.5 ± 115.8 (0.137) |
79.2 ± 130.4 (<0.001 *) |
298.6 ± 91.9 (0.243) |
258.2 ± 121.9 (0.004 *) |
373.4 ± 71.8 (0.506) |
348.1 ± 58.4 (0.324) |
0.18 ± 0.14 (0.186) |
0.23 ± 0.23 (0.549) |
* p < 0.05. SRF, subretinal fluid; CMT, central macular thickness; CCT, central choroidal thickness; BCVA, best-corrected visual acuity.